Literature DB >> 22101183

Non-chemotactic influence of CXCL7 on human phagocytes. Modulation of antimicrobial activity against L. pneumophila.

Carolina González-Cortés1, Cristina Diez-Tascón, José Manuel Guerra-Laso, María Cruz González-Cocaño, Octavio Miguel Rivero-Lezcano.   

Abstract

We have investigated the role of CXCL7 in the immune response of human phagocytes against the intracellular bacteria Mycobacterium tuberculosis and Legionella pneumophila. We have observed that polymorphonuclear neutrophil (PMN) chemotaxis induced by the supernatants of infected monocyte derived macrophages (MDM) may be attributed to CXCL8 rather than CXCL7, although both chemokines are present in large quantities. We have also found that CXCL7 is present not only in the supernatants of MDM, but also in the supernatants of PMN of some, but not all, individuals. Western blot analysis revealed that, in both MDM and PMN supernatants appeared two bands with molecular weights consistent with the platelet basic protein (PBP) and the neutrophil activating protein-2 (NAP-2) sizes. Regarding the influence on infected cells, recombinant NAP-2 enhanced the antimicrobial activity of IFNγ activated MDM against L. pneumophila, but not against M. tuberculosis. In addition, U937 cells transfected with a NAP-2 construct inhibited the intracellular multiplication of L. pneumophila, supporting its role in the modulation of the antimicrobial activity. Finally, U937 cells transfected with the NAP-2 construct showed an adherence that was dramatically enhanced when the substrate was fibronectin. We conclude that human phagocytes produce CXCL7 variants that may have a significant influence on the immune response against bacterial pathogens. Copyright Â
© 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101183     DOI: 10.1016/j.imbio.2011.10.015

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  7 in total

Review 1.  Emerging roles for platelets as immune and inflammatory cells.

Authors:  Craig N Morrell; Angela A Aggrey; Lesley M Chapman; Kristina L Modjeski
Journal:  Blood       Date:  2014-02-28       Impact factor: 22.113

Review 2.  Chemokines shape the immune responses to tuberculosis.

Authors:  Samantha R Slight; Shabaana A Khader
Journal:  Cytokine Growth Factor Rev       Date:  2012-11-16       Impact factor: 7.638

3.  Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera.

Authors:  Yuxia Hao; Ge Bai; Junping Wang; Longfeng Zhao; Kyle Sutherland; Jianfeng Cai; Chuanhai Cao
Journal:  BMC Immunol       Date:  2015-04-28       Impact factor: 3.615

4.  Ubiquitin-dependent proteolysis of CXCL7 leads to posterior longitudinal ligament ossification.

Authors:  Michiyo Tsuru; Atsushi Ono; Hideaki Umeyama; Masahiro Takeuchi; Kensei Nagata
Journal:  PLoS One       Date:  2018-05-21       Impact factor: 3.240

5.  Integrative Analysis of Human Macrophage Inflammatory Response Related to Mycobacterium tuberculosis Virulence.

Authors:  Pauline Bade; Fabrizio Simonetti; Stephanie Sans; Patricia Laboudie; Khadija Kissane; Nicolas Chappat; Sophie Lagrange; Florence Apparailly; Christine Roubert; Isabelle Duroux-Richard
Journal:  Front Immunol       Date:  2021-06-28       Impact factor: 7.561

6.  The pattern of cytokine production in vitro induced by ancient and modern Beijing Mycobacterium tuberculosis strains.

Authors:  Yih-Yuan Chen; Jia-Ru Chang; Wei-Feng Huang; Shu-Ching Hsu; Shu-Chen Kuo; Jun-Ren Sun; Horng-Yunn Dou
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

7.  Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.

Authors:  Komal Kedia; Jason P Wendler; Erin S Baker; Kristin E Burnum-Johnson; Leah G Jarsberg; Kelly G Stratton; Aaron T Wright; Paul D Piehowski; Marina A Gritsenko; David M Lewinsohn; George B Sigal; Marc H Weiner; Richard D Smith; Jon M Jacobs; Payam Nahid
Journal:  Tuberculosis (Edinb)       Date:  2018-07-18       Impact factor: 3.131

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.